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ABSTRACT
The progressive loss of residual renal function in perito-
neal dialysis patients is associated with increased mortal-
ity. It has been suggested that incremental dialysis may
help preserve residual renal function and improve patient
survival. Residual renal function depends upon both
patient related and dialysis associated factors. Maintain-
ing patients in an over-hydrated state may be associated
with better preservation of residual renal function but any
benefit comes with a significant risk of cardiovascular
consequences. Notably, it is only observational studies
that have reported an association between dialysis patient
survival and residual renal function; causality has not
been established for dialysis patient survival. The tenuous
connections between residual renal function and outcomes
and between incremental hemodialysis and residual renal
function should temper our enthusiasm for interventions
in this area.
Most patients embark on hemodialysis with some
degree of residual renal function. Its preservation is
strongly associated with patient and technique sur-
vival for peritoneal dialysis patients. Comparative
studies have suggested that initiating treatment with
peritoneal dialysis offers patients a survival advan-
tage over hemodialysis in the short term (1). In
most centers, patients treated by hemodialysis loose
residual renal function more rapidly than those on
peritoneal dialysis, and as such there has been
renewed interest in how patients initiate hemodialy-
sis and whether practice techniques influence loss of
residual renal function.
In the United States, payment for chronic hemod-
ialysis treatments are linked to achieving a defined
dose of dialysis, in terms of urea clearance (Kt/V),
and this has led to the practice of starting patients
on thrice weekly treatments designed to achieve the
target Kt/V, irrespective of residual renal function.
It has been questioned as to whether this approach
might lead to a more rapid loss of residual renal
function by reducing the drive to hyperfiltration of
the remaining functioning nephrons (2). As such
there has been renewed interest in initiating hemodi-
alysis as an adjuvant to residual renal function, akin
to incremental peritoneal dialysis.
Although a practioner of incremental hemodialy-
sis, I believe there are a number of factors that need
some consideration. Firstly, the greatest risk for
death for hemodialysis patients is in the first 90 days
after transition from nondialysis dependent chronic
kidney disease (CKD) to dialysis (3). Indeed, mortal-
ity in this period can be much greater for those initi-
ating hemodialysis compared to stage 5 CKD
patients opting for conservative nondialysis care (4).
The majority of studies which have investigated
transitioning to dialysis have shown that mortality is
predominantly associated with underlying patient
co-morbidity and lack of predialysis specialist neph-
rological care (3). This would suggest that the patient
trajectory is an important determinant of outcome,
as patients starting hemodialysis precipitously fol-
lowing an acute deterioration in renal function on a
background of CKD—(such as following an acute
coronary syndrome or development of cast nephrop-
athy) have much higher mortality rates than those
with slower progressive trajectories (5). The alterna-
tive scenario, CKD patients attending specialist
nephrology clinics, shows no benefit from earlier
compared to later initiation of dialysis (6).
On the other hand, earlier initiation of dialysis in
the IDEAL trial did not disadvantage patients, sug-
gesting that a planned start of dialysis in patients
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benefiting from prior specialist nephrology care did
not have increased mortality during the transition
phase. As such the introduction of thrice weekly
HD in this group of patients with a lower CKD
trajectory did not result in excessive mortality, sug-
gesting that hemodialysis per se may not carry a
major mortality risk. However, these patients pre-
dominantly dialyzed using arterio-venous fistulae,
rather than catheter access, whereas CKD patients
who have a sudden rapid deterioration in renal
function requiring dialysis, invariably dialyze using
catheters with increased risk for systemic bacteremia
and mortality (7).
Although there are many reported benefits for pre-
serving residual renal function in hemodialysis
patients (8), it is unclear whether its loss is a major
driver for the increased mortality observed during the
dialysis transition phase. Indeed, the Tassin center
approach, associated with one of the highest reported
survival rates for hemodialysis patients, renders more
than 90% of patients initiating dialysis anuric within
the first 90 days (9).There are no prospective trials
reporting that preservation of residual renal function
improves survival for hemodialysis patients.
Preserving Residual Function in Hemodialysis
Patients
The majority of hemodialysis patients are volume
overloaded prior to their dialysis session, and loose
both extracellular and intracellular fluid during
treatment (10). Bioimpedance devices have been
recently introduced into dialysis centers to aid clini-
cal decision making assessing fluid status in dialysis
patients (11). Cross-sectional and longitudinal
observational studies have reported that overhydrat-
ed dialysis patients do not have greater or better
preservation of residual renal function (12,13). So,
simply keeping patients overhydrated does not
appear to preserve residual function, but risks
hypertension and left ventricular hypertrophy.
On the other hand too rapid a removal of fluid
during hemodialysis risks hypotension (14), and
repetitive hypotensive episodes may potentially lead
to renal ischemia and premature loss of residual
renal function. Intradialytic hypotension is more
common in centers which target lower pre and post-
dialysis blood pressures (15), and patients attending
for dialysis at, or close to their target weight (16,17).
Although this approach risks anuria, blood pressure
is lowered and left ventricular hypertrophy regresses.
As most dialysis centers do not regularly measure
residual function, it remains to be established
whether preventing intradialytic hypotension by
using bioimpedance and dialysis machine technology
(18), can preserve residual renal function. However,
observational studies have shown that patients with
more intradialytic hypotensive episodes (19), and
those deliberately dialyzed to achieve lower biom-
pedance targets (20) lost residual renal function
quicker. The more frequent nocturnal hemodialysis
trial reported faster loss of residual renal function
with more frequent and longer dialysis sessions (21).
Whether this was due to achieving greater clearances
or more hypotensive episodes remains unclear.
In contrast, a Spanish study reported better preser-
vation of residual renal function in patients hemodia-
lyzed twice weekly compared to thrice weekly, with a
similar loss of residual renal function to peritoneal
dialysis patients (22). However, this study was con-
founded by lead time bias, as patients with greater
residual renal function initiating dialysis were dia-
lyzed twice weekly, whereas those with lower residual
renal function were dialyzed thrice weekly. Similarly
other studies advocating twice weekly hemodialysis
are also confounded by retrospective analysis, no
propensity matching with differences in lead time
and patient co-morbidity (23,24).
If twice a week hemodialysis were to offer an
advantage in terms of preserving residual renal
function, then it may do so by keeping patients vol-
ume expanded and reducing episodes of intradialytic
hypotension (25). However, this practice risks wors-
ening blood pressure control and left ventricular
hypertrophy (25). Supplemental thrice weekly he-
modialysis would potentially control over-hydration
better than twice weekly treatments, and also, by
reducing the amount of fluid to be removed during
any one session, would potentially reduce the risk
of intradialytic hypotension. This is supported by
recent prospective trial using incremental dialysis
which reported very few intradialytic hypotensive
episodes and observed that residual renal function
was better preserved than that reported from his-
toric series but this study (26).
However, it must be recognized that factors other
than hypovolemia and episodes of intradialytic hypo-
tension determine the loss of residual renal function.
Due to the paucity of prospective studies in hemodi-
alysis patients, most of the information on residual
renal function emanates from peritoneal dialysis
patients. These studies have consistently reported
that the loss or residual renal function depends upon
the original renal disease, typically faster loss for cys-
tic and diabetic kidney disease compared to glomeru-
lonephritis (27). Similarly, those with proteinuric
renal diseases are more likely to have a faster loss of
RRF (28), as are those with peripheral and cardio-
vascular disease (29). Residual renal function tends
to be lost earlier in those patients initiating dialysis
with lower residual renal function, but this could be
confounded by lead time bias. Although angiotensin
enzyme converting enzyme inhibitors and angioten-
sin receptor blockers have been associated with pres-
ervation of residual renal function, they have not
been shown to have any protective effect in hemodi-
alysis patients (26,30).
Measurement of Residual Renal Function
Incremental dialysis depends on the ability to
measure residual renal function and then adjusting
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the dose of dialysis accordingly. Unfortunately there
is no simple blood test to readily assess residual
renal function; the obvious measure, urine volume,
is an inaccurate assessment. The “gold” standards
of inulin, 51chromium ethylenediaminetetra-acetic
acid (EDTA), and iothalamate radiocontrast clear-
ance are more accurate for determining residual
renal function in dialysis patients than urine collec-
tions but are impractical in clinical practice. As
such, 24 hour urine collections remain the standard
method, with clinical guidelines recommending cal-
culating the mean of both creatinine and urea clear-
ance, as urea underestimates and creatinine
overestimates inulin clearance, and then adjusting
clearance to a body surface area of 1.73 m2 (31).
Putting aside the problems of reliably collecting
24 hour urine collections, both serum urea and cre-
atinine are affected by dietary protein intake, and
creatinine also depends upon muscle mass and phys-
ical activity, and changes in intestinal bacteria flora
alter urea and creatinine gastrointestinal losses. In
addition, there is the effect of chromagens which
accumulate in CKD and interfere with the standard
laboratory colorimetric Jaffe reaction (32). Another
confounder is the timing of the urine collection in
relation to dialysis sessions, especially when patients
are dialyzed twice or thrice weekly. The composite
urea and creatinine clearance then has to be
adjusted to body size. It is many years since the ori-
ginal equations linking anthropomorphic measure-
ments to body surface area were made, and over
time populations have changed, with increasing
body fat (33). As such the original link between
body surface area and muscle mass, particularly in
the dialysis population, with an increased risk of
sarcopenia may no longer hold (34,35).
As such, although 24 hour urine collections under-
pin measuring residual renal function in dialysis
patients, one has to appreciate the limitations of the
measurements and confounding errors. The final dif-
ficulty is then equating this measured residual renal
clearance with a dialysis derived urea clearance,
based on an estimate of total body water (36,37).
Summary
Although there is a marked increased risk of mor-
tality as CKD5 patients transition to hemodialysis,
it is most likely that this is due to patient co
-morbidity and unplanned dialysis starts, rather
than simply the loss of residual renal function.
Maintaining residual renal function potentially
allows the patient a better quality of life with more
liberal diet and fluid intake. However, there is no
definitive evidence that preserving residual renal
improves patient survival. Loss of residual renal
function is predominantly determined by the
primary renal disease and patient co-morbidity.
However, hypovolemia, and repetitive episodes of
hypotension are associated with faster loss of resid-
ual renal function, and as such incremental dialysis
may help to preserve residual renal function. As
dialysis dosing is not simply a matter of small solute
clearance, and dialysis should also be prescribed to
achieve volume control and maintain electrolyte and
acid base balance. Although there are financial and
patient benefits for twice weekly incremental dialy-
sis, it is more likely that a thrice weekly approach
will better preserve residual renal function.
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